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INTRODUCTION 
“For all the happiness that mankind can gain  
   it is not in pleasure but in relief from pain” 
                                                                         -    JOHN DYRDEN  
Pain is a fundamental biological phenomenon. The international 
association for the study of pain has defined pain as “an unpleasant 
sensory and emotional experience associated with actual or potential  
tissue damage”. Pain is always underestimated and under treated. The 
relief of pain during surgery is the main part of anaesthesia. 
In 1784 James Moore used mechanistic concepts to promote neural 
compression as a useful technique for the provision of surgical 
anaesthesia. 
In 1855, it was proposed that neurologic pain can be treated by 
circum-neural injection of pain relieving drug. At the same year Gadecke 
(Germany) isolated alkaloid from leaves of coca plant. In 1860 Albert 
Nieemann was successful in isolating and naming the alkaloid from the 
leaves of erythroxylon coca. 
In 1880 Halsted and Hall began their work on regional anaesthesia. 
In 1884 Hall reported that injection of cocaine into the forearm provided 
analgesia below the point of injection. Additional blocks were then 
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performed on the brachial plexus, infraorbital nerve and sciatic nerve, all 
for operative surgery.  
After introduction of barbiturate and cyclopropane, the enthusiasm 
for block anaesthesia waned in early 1940s. In current recent years 
however, the technique has had resurgence, due in large part to increased 
understanding of neural plasticity and the possibility of minimizing 
hospital stay length by effective use of regional block anaesthesia. 
 Several techniques have been used to prolong the duration of 
regional anaesthesia. The continuous infusion of local anaesthetics through 
catheters in nerve blocks are extensively studied and recently opioids as 
adjuvants to local anaesthetic solutions were used. 
          Surgery in the leg results in severe and sustained postoperative pain. 
This postoperative pain is difficult to control with oral medications. Single 
shot nerve block is very effective for postoperative pain control in 
orthopaedic and surgical procedures. 
Sciatic nerve has a wide sensory distribution, hence it can be used 
together with saphenous or femoral nerve block for any surgical 
procedures below the knee. This form of anaesthesia avoids 
sympathectomy associated with neuraxial blocks and may therefore be 
advantageous when any shift in hemodynamics could be deleterious. 
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Several experimental and clinical studies have shown that Alpha - 2 
adrenergic agonists like clonidine were able to prolong sensory and motor 
blockade. 
 This study is designed to assess the efficacy of the addition of an 
alpha -2 adrenergic agonist, Clonidine to local analgesic solution in sciatic 
femoral block for lower limb surgery. 
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AIM OF THE STUDY 
To assess the efficacy of CLONIDINE AS AN ADJUVANT TO 
ROPIVACAINE IN SCIATIC FEMORAL NERVE BLOCK in respect 
to 
1. Onset and duration of sensory blockade 
2. Onset and duration of motor blockade 
3. Duration of postoperative analgesia 
4. Haemodynamic changes 
5. Sedation score and 
6. Side effects  
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ANATOMICAL CONSIDERATIONS 
Knowledge of the formation of sciatic and femoral nerve and of its 
distribution is absolutely essential to the intelligent and effective use of 
sciatic femoral nerve block. As the sciatic nerve is deeply situated within 
the muscular plane, there are various approaches to sciatic nerve blockade. 
FORMATION OF SCIATIC NERVE: 
The largest of the four major nerves supplying the leg is the sciatic 
nerve (L4-L5, S1-S3). The sciatic nerve arises from the sacral plexus, 
where it is nearly 2 cm in width as it leaves the pelvis in company with 
posterior cutaneous nerve of the thigh. It passes from the pelvis through 
sacrosciatic foramen beneath the lower margin of pyriformis muscle and 
between the tuberosity of the ischium and greater trochanter of the femur. 
The nerve becomes superficial at the lower border of the gluteus maximus 
muscle. From there it courses down the posterior aspect of the thigh to the 
popliteal fossa, where it divides into tibial and common peroneal nerves. 
Branches supplying the posterior thigh are given off during the descent of 
the nerve to the popliteal space. The sciatic nerve supplies sensory 
innervations to the posterior thigh and entire leg and foot from just below 
the knee 
 
DISTRIBUTION OF SCIATIC NERVE 
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Tibial nerve:  
                The tibial part of the sciatic nerve, either before or after its
separation from the common peroneal nerve, supplies branches to all muscles 
in the posterior compartment of thigh (long head of biceps femoris, 
semimembranosus, semitendinosus) except the short head of biceps femoris,
which is innervated by the common fibular part. The tibial nerve descends 
through the popliteal fossa, enters the posterior compartment of leg and
continues into the sole of the foot. 
The tibial nerve innervates:  
1. All muscles in the posterior compartment of leg. 
2. All intrinsic muscles in the sole of the foot except the first two dorsal 
interossei muscles, which are innervated by the deep fibular nerve. 
3. Skin on the posterolateral side of the lower half of the leg and medial side
of the ankle, foot, and little toe, and skin on the sole of the foot and toes. 
Common peroneal nerve : 
            The common peroneal part of the sciatic nerve innervates the short 
head of biceps femoris in the posterior compartment of thigh and then
continues into the lateral and anterior compartments of leg and onto the foot 
The common peroneal nerve innervates:  
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1. All muscles in the anterior and lateral compartments of leg.  
2. One muscle (extensor digitorum brevis) on the dorsal aspect of the foot. 
3. The first two dorsal interossei muscles in the sole of the foot.  
4. Skin over the lateral aspect of the leg, and ankle, and over the dorsal aspect 
of the foot and toes. 
FEMORAL NERVE: 
                 The femoral nerve (L2-L4) proceeds from the lumbar plexus in the 
groove between psoas major and iliac muscles, where it enters the thigh by
passing deep to the inguinal ligament. At the level of inguinal ligament, the
femoral nerve lies anterior to iliopsoas muscle and slightly lateral to the
femoral artery. Immediately after passing under the inguinal ligament, the
femoral nerve divides into anterior and posterior divisions. 
Branches of the femoral nerve include:  
1. Anterior cutaneous branches, which penetrate deep fascia to supply skin on
the front of the thigh and knee.  
2. Numerous motor nerves, which supply the quadriceps femoris muscles
(rectus femoris, vastus lateralis, vastus intermedius, and vastus medialis
muscles) and the sartorius muscle.  
3. One long cutaneous nerve, the saphenous nerve, which supplies skin as far 
distally as the medial side of the foot. 
DISTRIBUTION OF FEMORAL NERVE 
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TECHNIQUE OF BLOCKADE: 
SCIATIC NERVE BLOCK – POSTERIOR APPROACH 
ANATOMICAL LANDMARKS: 
                Important bony structures for posterior sciatic nerve block include 
greater trochanter of femur, posterior superior iliac spine and sacral hiatus. The
greater trochanter can be identified by palpating the lateral aspect of proximal
femur, walking  upwards, one finger tends to fall off the bone when the apex of 
greater trochanter is reached. The posterior superior iliac spine is the bony
prominence at the posterior end of iliac crest. Palpation from the iliac crest can
help to correctly identify the posterior superior iliac supine. 
POSITION OF THE PATIENT: 
               The posterior approach to the sciatic nerve block is with the patient
lying on the side opposite the one to be blocked rolled forward onto the flexed
knee, with the heel in opposition to the knee of the outstretched dependent leg.
TECHNIQUE: 
               The patient is placed in lateral (sims) position. The first line is drawn 
between points made over the upper aspect of greater trochanter of the femur
and posterior superior iliac spine. This line is bisected and a perpendicular line 
is drawn passing downwards from its midpoint. A second line is drawn from
the sacral hiatus to the greater trochanter. The point at which this line
ANATOMICAL LANDMARKS – SCIATIC NERVE 
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intersects with the perpendicular line marks the point of insertion. The area is
prepared and draped. A skin wheal performed with 1ml of lignocaine (1%) 
using a hypodermic needle at the point of insertion. A 21 gauge short-beveled 
and 50mm long Teflon-coated needle is connected to the peripheral nerve
stimulator which is set at 1 mA with 2 Hz frequency. The needle is inserted 
perpendicular to both sides and oriented 90 degrees to all the planes and varied 
slowly until muscle twitching of the leg and foot is observed. The stimulation
is gradually reduced to lower than 0.5mA while muscle twitching is observed. 
The volume of local anaesthetics (0.75% ropivacaine) is 18 ml. 
COMPLICATIONS: 
1. Neural injury is rare with the use of nerve stimulator, but still possible. 
2. Local anaesthetic toxicity due to intravascular injection. Hence slow
injection and carefull aspiration should be done before giving the drug. 
3. Haematoma due to puncture of inferior gluteal vessels. 
Other approaches to sciatic nerve blockade are anterior or beck approach,
inferior approach, subgluteal approach and lateral approach. 
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FEMORAL NERVE BLOCK: 
ANATOMICAL LANDMARKS 
The main landmarks for femoral block are the anterior superior iliac 
spine, the pubic tubercle, inguinal ligament, inguinal crease and femoral 
artery.  
TECHNIQUE: 
The patient is placed in supine position. The pubic tubercle can be 
palpated three finger breadth from the midline, along the upper border of 
the pubis. The inguinal ligament is outlined by a line connecting the 
anterior superior iliac spine and pubic tubercle. The femoral artery lies 
approximately at the intersection of the medial third and lateral two thirds 
of the inguinal ligament (mid inguinal point). The femoral nerve which is 
found lateral to femoral artery is noted and marked as insertion point. The 
area is prepared and draped. A skin wheal performed with 1ml of 
lignocaine (1%) using a 23g hypodermic needle at the point of insertion. A 
23 gauge short-beveled and 50mm long Teflon-coated needle is connected 
to the peripheral nerve stimulator which is set at 1 mA with 2 Hz 
frequency. The needle inserted and oriented in a 45 degree cephalad and 
advanced slowly until the appropriate muscle response is observed-
quadriceps contraction with resultant rhythmic patellar movement. The 
ANATOMICAL LANDMARKS – FEMORAL NERVE 
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needle position is adjusted while decreasing the current to 0.5 mA with the 
maintenance of muscle response. The volume of local anaesthetics (0.75% 
ropivacaine) is 12 ml. 
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                                   PHYSIOLOGICAL CONSIDERATIONS 
Pain perception requires noxious stimuli. It is transformed from its 
native form by the activated nociceptors into electrical signals which are 
then transmitted along the corresponding nociceptive fibres. These fibres 
in turn synapse onto second order neurons in the spinal cord. These 
interneurons are located in the dorsal horn. It is at these interneurons 
where the initial modulation of nociceptive input occurs. From the spinal 
cord nociceptive input is transmitted to the brain stem, thalamus and 
cortex. 
 
Peripheral neuroanatomy of nociception 
       C and A delta fibres are the main peripheral nociceptors. The skin, 
joints and periosteum are richly innervated with C and A delta nociceptors.  
A delta fibres are responsible for the sensation of first pain (the initial 
sharp pain experienced following an injury). C fibres are unmyelinated and 
are responsible for second pain (the slowly building throbbing burning 
pain experienced following an injury). 
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CLASSIFICATION OF SENSORY FIBRES 
Sensory 
receptors 
Speed of 
transmission 
Sensory function Myelination 
C Fibres 0.5 -2m/sec 
Noxious chemical, 
Mechanical, thermal 
activation (Slow 
burning second pain)
Unmyelinated 
A-Alpha fibres 70 -120m/sec 
Noxious chemical 
thermal, mechanical 
stimuli, (sharp fast, 
first pain) 
Lightly 
myelinated 
A-Beta fibres 30 -70m/sec 
Non painful, light, 
touch, pressure, 
vibration 
proprioception 
Heavily 
myelinated 
A-Gamma 
fibres 
30-70m/sec 
Proprioception/Motor 
to muscle spindle 
Myelinated 
A-Delta fibres 12 -30 m/sec Pain, cold, touch Myelinated 
B fibres 3 -15 m/sec 
Preganglionic 
autonomic 
(sympathetic) 
Myelinated 
 
Peripheral neurochemistry and neurotransmitters 
Commonly released inflammatory mediators implicated in pain and 
hyperalgesia include bradykinins, potassium, substance P, cytokines, 
histamine, serotonin and prostaglandins.These peripheral neurotransmitters 
either activate or sensitise the peripheral nociceptors to pain. 
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PERIPHERAL NEURO CHEMISTRY ALGOGENIC AGENTS 
Algogenic Agent Action on nociceptors 
Bradykinin Activates 
Potassium  Activates 
Substance P Sensitizes 
Arachidonic acid Sensitizes 
Cytokiness Sensitizes 
Serotonin Sensitizes 
Nor adrenaline 
High concentration activates and 
sensitizes after injury. 
 
Peripheral alpha 2 receptors 
Alpha 2 adrenoreceptors are located on primary afferent terminals, 
on neurons in the superficial laminae of the spinal cord, and within several 
brainstem nuclei implicated in analgesia, supporting the possibility of 
analgesic action at peripheral, spinal, and brainstem sites. 
Clonidine enhances both sensory and motor blockade from 
peripheral nerve injection and epidural/spinal injection of local 
anaesthetics. Clonidine blocks conduction of C and A gamma fibers and 
increase potassium conductance in isolated neurons and intensifies 
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conduction block of local anaesthetics. Local vasoconstriction resulting in 
reduced absorption from injection site was another point of discussion, but 
compared with adrenaline as adjuvant it failed to influence plasma levels, 
indicating a direct action on nerve. 
PAIN PATHWAY: 
SPINAL CORD 
The gray matter of the spinal cord is divided into ten lamina with 
lamina I – IV representing the dorsal horn. The dorsal horn is capped by 
the Lissauer’s tract which consists of branches of cutaneous A and C  
fibres and few visceral afferents. 
Nociceptive fibres terminate in the superficial layers of lamina I & II 
while the non-painful myelinated fibres terminate in the deeper layers of 
lamina III, IV. Lamina II has the highest concentration of opioid receptors 
in the spinal cord. Modulation and inhibition of nociception may occur at 
this level through the use of opioids (systemic and neuraxial). 
ASCENDING SENSORY PATHWAYS 
Peripheral sensory neurons synapse onto the secondary interneurons 
of the dorsal horn. The axons of the non nocieptive secondary neurons 
travel ipsilaterally in the dorsal columns of the spinal cord as fasciculus 
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cuneatus (upper body through T6) and fasciculus gracilis (lower body 
below T6) and synapse in thalamus. 
The axons of the nociceptive secondary neurons after synapsing, travel 
contralaterally in the anterolateral aspects of the spinal cord as the 
neospinothalamic and paleospinothalamic tract. 
Neospinothalamic tract carries fine discrimination of pain eg. 
Location, intensity and first pain. 
Paleospinothalamic tract responds to noxious stimuli. The paleo 
spinothalamic tract synapses in the thalamus, hypothalamus and limbic 
system and plays a role in emotional aspects of pain via limbic system. 
The thalamus has multiple connections to limbic system and cortex. 
DESCENDING INHIBITORY PATHWAYS 
The descending controls of pain project specifically onto laminas 
I,II,V of the dorsal horn from mesencephalon, raphenuclei and reticular 
tract. The mesencephalon is rich in opioid receptors. This area sends 
excitatory transmissions to the rostroventral medulla which sends 
nordrenaline and serotonin to inhibitory tracts via the dorsolateral 
funiculus to lamina I, II, V of spinal cord.  
The noradrenaline and serotonin fibres mediate transmission 
between the primary afferents and the secondary neurons of the dorsal 
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horn. Increased activity of these fibres leads to increased inhibition of pain 
transmission. 
Location of Alpha2 receptors 
Primary afferent terminals, on neurons in the superficial laminae of 
spinal cord and brainstem nuclei. 
Location of opioid receptors (central)  
         Opioid receptors are found in the various regions in CNS namely, 
cerebral cortex, limbic cortex (anterior and posterior amygdala, 
hippocampus, hypothalamus, medial thalamus, mid brain, periaqueductal 
gray matter, extrapyramidal areas, substantia gelatinosa and sympathetic 
preganglionic neurons. 
Opioid receptors are also found in the cardiac sympathetic fibres, 
cardiac branches of vagus, adrenal medulla and gastro intestinal tract. 
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                                   NERVE STIMULATOR 
History: 
 The first description of electrical stimulation to locate the brachial 
plexus was recorded by Perthes in 1912. However, the acceptance of 
peripheral nerve blocks was not realized until the 1960s when electronic 
advances and the consequent introduction of more convenient solid-state 
units were made. Greenblatt and Denson have demonstrated that motor 
nerves can be stimulated without eliciting pain and that the current 
required to stimulate the nerve depends on the distance between the needle 
and the target nerve.  
The mapper–locator is an excellent solution to reduce the 
dependency of the anaesthesiologist on anatomical knowledge and 
variations, and also increases the success rate compared to the paraesthesia 
technique. It is helpful in defining anatomical land marks for the entry 
point, especially in growing children ,obese patients and in case of 
distorted anatomy. 
Components: 
The nerve stimulator case contains an on/off switch and a dial, 
selecting the amplitude of the current. It has two leads to complete the 
circuit. One lead is connected to an ECG skin electrode and the other lead 
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to the locating needle. The polarity of the leads should be clearly indicated 
and colour-coded with the negative lead being attached to the needle. 
Mechnism of action: 
A small current (0.25-0.5mA) is used to stimulate the nerve fibres 
causing the motor fibre to contract. The frequency is set at 1-2Hz. The 
duration of the stimulus should be short (1-2ms) to generate painless motor 
contraction. 
The nerve stimulator is battery operated to improve patient safety. 
Nerve location can be very accurately defined especially when low 
currents are used. The success rate of technically difficult nerve blocks can 
be increased by using a nerve stimulator. A sciatic nerve block with a 
success rate of over 90% can be achieved in experienced hands, compared 
to about 50% without using a nerve stimulator. 
Nerve blocks can be performed while the patient is anaesthetized or 
heavily sedated as the response is visibly monitored with no need to elicit 
paraesthesia. However, the use of neuromuscular blocking agents will 
abolish any muscular contractions 
Problems in practice and safety features: 
Higher currents will stimulate nerve fibres even if the tip of the 
needle is not adjacent to the nerve. The muscle fibres themselves can also 
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be directly stimulated when a high current is used. In both situations the 
outcome will be an unsuccessful block once the local anaesthetic solution 
has been injected. 
It is not recommended to use nerve stimulator designed to monitor 
the extent of neuromuscular blockade for regional nerve blocks. These are 
high output devices which can damage the nervous tissue. 
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                     PHARMACOLOGY OF ROPIVACAINE 
Ropivacaine is a new aminoamide local anaesthetic. It is the 
monohydrate of the hydrochloride salt of 1–propyl–2pipecoloxylidide. 
Pipecoloxylidides were first synthesized in 1957 and have been in clinical 
use of more than 30 years. Ropivacaine has a propyl group on the 
piperidine nitrogen atom of the molecule. 
 The Pipecoloxylidides are chiral drugs because the molecules 
possess an asymmetric carbon atom and they may have left – (sinister) or 
right (rectus) handed configuration. 
 Ropivacaine hydrochloride is an odourless, clear liquid and is 
manufactured in the pure S-enatiomer form by the  alkylation of              
S–enantiomer of dibenzoy–L –tartaric acid. It has an enantiomeric purity 
of 99.5%. 
PHYSIO-CHEMICAL PROPERTIES 
The physio-chemical properties of Ropivacaine are as follows: 
1. Molecular weight (base)   -  274 
2. pKa       -   8.1 
3. Partition Coefficient (N Heptane buffer) -   2.9 
4. Mean uptake ratio TMsense nerve  -   94 
 
ROPIVACAINE HYDROCHLORIDE 
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PHARMACOLOGIC PROPERTIES 
 The relative lipid solubility of ropivacaine as measured by 
partitioning studies between N-heptane buffer and relative mean uptake 
into rat sciatic nerves, shows ropivacaine to be intermediate between 
bupivacaine and lignocaine. Plasma – protein binding is marginally less 
than of bupivacaine but the pKa is identical. It has a moderate onset,long 
duration of action with relative potency of 6.   
MECHANISM OF ACTION 
 Ropivacaine acts by reversible blockade of the sodium ion channel 
found in the nerve cell membranes. The decreased permeability of the 
membrane to sodium ions produce a decrease in depolarisation velocity 
and an increase in excitable threshold, temporarily preventing the 
transmission of nerve impulses. The progression of anaesthesia is related 
to the diameter, myelination and conduction velocity of affected nerve 
fibers.   
The order of loss of nerve function clinically is as follows: 
1. Pain 
2. Temperature 
3. Touch 
4. Proprioception 
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5. Skeletal muscle tone. 
PHARMACOKINETICS 
In human volunteers the pharmacokinetic characteristics of 
ropivacaine have been determined after intravenous infusion 
Clearance      0.82 ± 0.16 litres /min 
     Plasma protein binding    94 % 
Volume of distribution at steady state   59 ± 7 liters  
Terminal elimination ½ life   111 ± 62min 
Metabolism in liver is by aromatic hydroxylation by cytochrome P450 
1A to 3 – hydroxyl ropivacaine. 
Excretion-86% via the kidney 1%-unchanged drug, rest as metabolites. 
The higher clearance of ropivacaine over bupivacaine is advantageous in 
terms of lesser systemic toxicity. 
ABSORPTION 
 The systemic concentration of ropivacaine is dependent on the total 
dose and concentration of drug administered, the route of administration, 
the patient’s haemodynamic condition and the vascularity of the 
administration site. From the epidural space, ropivacaine shows complete 
and biphasic absorption.  The slow absorption is the rate limiting factor in 
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the elimination of ropivacaine, which is why the terminal half life is longer 
after epidural than after intravenous administration.  
DISTRIBUTION 
After intravascular infusion, ropivacaine has a steady state volume 
of distribution of 59 ±7 litres. Ropivacaine is 94% protein bound, mainly 
to α1acid glycoprotein. An increase in total plasma concentration during 
continuous epidural infusion has been observed, related to postoperative 
increase of α1acid glycoprotein. Variation in unbound, i.e. 
pharmacologically active concentrations have been less than in total 
plasma concentrations. Ropivacaine readily crosses the placenta and 
rapidly equilibrium is reached in regard to unbound concentration. 
METABOLISM 
 Ropivacaine is extensively metabolized in the liver, mainly by 
aromatic hydroxylation mediated by cytochrome P450 1A with 86% of a 
single dose being metabolized and only 1% being excreted unchanged in 
urine. The major metabolites are 3–hydroxy ropivacaine 2,6 
pipecoloxylidide (2.8%) and 4-hydroxy ropivacaine(0.4%). Small quatities 
of  3- hydroxyl pipecoloxylidide and 2-hydroxy methyl ropivacaine are 
also formed. Cytochrome P1A2 is the major enzyme system responsible 
for formation of 3-hydroxy ropivacaine while cytochrome 3A4 is 
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responsible for the formation of 2,6 pipecoloxylidide. Because of the 
dependence on the cytochrome system for metabolism, there is a potential 
for the metabolism of ropivacaine to be inhibited by competitive drugs 
such theophylline and imipramine. The quinolones, fluoxamine and 
verapamil are potent inhibitors of cytochromeP1A2 and could reduce the 
metabolism of ropivacaine. In animal studies 3- hydroxyl and 4- hydroxyl 
ropivacaine have been shown to have a weak local anesthetic activity but 
this is not proven in clinical use. There is no evidence that ropivacaine 
undergoes racemisation during metabolism or elimination.   
ELIMINATION 
 The kidney is the main excretory organ for most local anaesthetic 
metabolites. In total 86% of the ropivacaine dose is excreted in the urine 
after intravenous administration of which only 1% relates to unchanged 
drug. Ropivacaine has a mean total plasma clearance of 387 ±107 ml/min. 
The mean ± SD terminal half life is 1.8 ± 0.7 h after intravascular 
administration and 4.2 ± 1.0 h after epidural administration. 
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PHARMOCODYNAMICS 
Primary Pharmocodynamics (Animal Studies) 
 These studies showed that ropivacaine at low concentration 
produced a profound rapid block of both A delta and C fibres and was 
more potent than similar low concentrations of bupivacaine. 
 At higher concentrations, ropivacaine and bupivacaine had similar 
blocking properties. A delta fibre blocking was 16% greater than 
bupivacaine and the degree of C fibre block was similar with both the 
drugs. 
Ropivacaine is a potent producer of frequency (or use) dependant 
blocks (i.e) a block that occurs only when the fibre is stimulated. 
Ropivacaine blocked ‘C’ fibres faster than A fibres. 
 Low pKa and high lipid solubility of a local anaesthetic drug 
favoured A over C fibre block. The lower lipid solubility of ropivacaine 
over bupivacaine is presumed to retard penetration into myelin sheath. 
 This greater degree of differential block with ropivacaine at low 
concentration and the property of producing frequency dependent block 
were considered to offer clinical advantages in providing analgesia with 
minimal motor block. 
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Secondary Pharmocodynamics:  
Addition of epinephrine to ropivacaine has no limiting effect on the 
systemic absorption of ropivacaine. Systemic absorption can produce 
effects on the central nervous and cardiovascular systems. At blood 
concentration achieved with therapeutic doses, changes in cardiac 
conduction, excitability, refractoriness, contractility and peripheral 
vascular resistance are minimal. However, toxic blood concentrations 
depress cardiac conduction and excitability, which may lead to 
atrioventricular block, ventricular arrhythmias and to cardiac arrest. In 
addition, myocardial contractility is depressed and peripheral 
vasodilatation occurs, leading to decreased cardiac output and arterial 
blood pressure. 
 Ropivacaine can produce central nervous system stimulation, 
depression or both. Apparent central stimulation is usually manifested as 
restlessness, tremors, shivering, progressing to convulsions, followed by 
depression and coma, progressing to respiratory arrest. However, 
ropivacaine has a primary depressant effect on the medulla . 
ADVERSE REACTIONS 
 A major cause of adverse reactions may be due to excessive plasma 
levels that may be due to over dosage, unintentional intravascular injection 
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or slow metabolic degradation. Most adverse events reported were mild 
and transient. 
CENTRAL NERVOUS SYSTEM REACTIONS 
        These are characterized by excitation and/or depression. Restlessness, 
anxiety, dizziness, tinnitus, blurred vision or tremors may occur, possibly 
proceeding to convulsions. However, excitement may be transient or 
absent with depression being the first manifestation. This may quickly be 
followed by drowsiness, unconsciousness and respiratory arrest. Other 
effects may be nausea, vomiting, chills and constriction of pupils. 
CARDIOVASCULAR SYSTEM REACTIONS 
 High doses or unintentional intravascular injection may lead to high 
plasma levels and related depression of myocardium, decreased cardiac 
output, heart block, hypotension, bradycardia and ventricular arrhythmias 
including ventricular tachycardia and ventricular fibrillation and possibly 
cardiac arrest. 
Preparations available: 
0.2% 
0.5% 
0.75% 
1%. 
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Uses: 
1. Infiltration anaesthesia 
2. Peripheral nerve blocks 
3. Lumbar extradural block (Especially Labour) 
4. Subarachnoid block 
5. Caudal block 
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PHARMACOLOGY OF CLONIDINE 
Clonidine hydrochloride is a centrally acting selective partial α2  
agonist introduced in early 1960s, it was during its use as a nasal 
decongestant that its anti–hypertensive property was found out. 
Subsequently more insights into the pharmacological properties has led to 
its use in clinical anaesthesia practice as well. 
 Clonidine hydrochloride is an imidazoline derivative and exists as a 
mesomeric compound. The chemical name is 2-(2,6 dichlorophenylamino) 
-2 imidazoline hydrochloride. The structural formula is C9H9Cl2N3HCl. 
 The molecular weight is 266.56. Clonidine hydrochloride is a white 
crystalline odourless powder with a bitter taste. It is produced by chemical 
synthesis and it is soluble in alcohol and water. Clonidine improves the 
quality of anaesthesia, provides a more stable cardiovascular course during 
anaesthesia, and reduces the dose requirement of the anaesthetic agent. 
Clonidine potentiates the anaesthetic action of the local anaesthetics with 
fewer side effects in peripheral nerve blocks and central neuraxial 
blockade. 
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AVAILABILITY  
 Available as one ml ampoule containing 150 micrograms. It should 
be stored below 25 degree celsius. It is also available in tablet, containing 
100 micrograms. 
MECHANISM OF ACTION  
 Clonidine is a centrally acting partial α2 adrenergic agonist with a 
selectivity ration of 220: 1 in favour of α2 receptors. The three subtypes of 
α2 receptors are α2a, α2b, α2c. α2a receptors mediate sedation, analgesia, 
sympatholysis. α2b receptors mediate vasoconstriction and anti- shivering. 
The startle response may reflect the activation of α2c receptors. The drug 
is lipid soluble, penetrates the blood brain barrier to reach the 
hypothalamus and medulla when injected epidurally. It stimulates the 
inhibitory α2 adrenoreceptors to reduce the central neural transmission in 
the spinal neurons Inhibition of substance-P release is believed to be 
involved in the analgesic effect. 
 The α2 adrenoreceptors are located on the afferent terminals of both 
peripheral and spinal neurons in the superficial laminae of the spinal cord 
and with in several brain stem nuclei implicated in analgesia. The 
superficial laminae contain three groups of neurons: tonic, adapting, 
single- spike firing, all of which receive their primary sensory input from 
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Aδ and C fibres. Clonidine inhibits voltage gated Na + and K+ channels 
and suppresses the generation of action potentials in tonic- firing spinal 
dorsal horn neurons, contributing to analgesic effect. The ability of 
clonidine to modify the function of potassium channels in the CNS (Cell 
membrane become hyperpolarized) may be the mechanism for profound 
decrease in anaesthetic requirements. 
 Another contribution to analgesic effect may be through the release 
of acetylcholine in the neuraxial region. The α2 adrenergic agonists also 
enhance analgesia from intraspinal opioids. Sedation is produced by its 
action on locus ceruleus. 
 Clonidine affects the blood pressure in a complex fashion after 
neuraxial or systemic administration because of opposing action at 
multiple sites. In the nucleus tractus solitarius and locus ceruleus of the 
brain stem, activation of post-synaptic α2 adrenoreceptors reduces 
sympathetic drive. It also activates nor- adrenergic imidazoline preferring 
binding sites in the lateral reticular nucleus producing hypotension and 
anti- arrythmogenic ation. In the periphery it acts on pre-synaptic α2 
adrenoreceptors at sympathetic terminals to reduce the release of          
nor-epinephrine causing vasorelaxation and reduced chronotropic drive. 
The brainstem and the peripheral effects of α2 adrenoreceptor stimulation 
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are counterbalanced by the direct peripheral vasoconstriction through its 
action on α2 adrenoreceptors from the circulating concentrations of 
clonidine.  
Sedation is a desired property. Clonidine produces a dose dependent 
sedation at the dose of 50 micrograms or more in less than 20 minutes 
regardless of the route of administration. 
 In peripheral nerves it produces a minor degree of blockade at high 
concentrations with some preference for C- fibres and this effect may, in 
part enhance the peripheral nerve block when added to local anaesthetics, 
probably because the α2 adrenoreceptors are lacking on the axons of 
peripheral nerves. 
PHARMACOKINETICS 
 Clonidine is well absorbed orally and is nearly 100% bio available 
and reaches peak plasma concentration within 60 to 90 minutes. The mean 
half life of the drug in plasma is about 9 to 12 hours, with approximately 
50% metabolized in the liver where as is it is excreted in an unchanged 
form by the kidney, and its half- life can dramatically increase in the 
presence of impaired renal function. 
           Clonidine is highly lipid soluble and readily distributes into 
extravascular sites including the central nervous system. 
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300 micrograms intravenously over 10 min produces: 
Distribution t½  :  11± 9 minutes 
Elimination t½  : 9± 2 hours        
Volume of distribution :  2.1± 0.4 l/kg 
Plasma protein binding : 20 - 40% in vitro 
METABOLISM  
         Clonidine is approximately 40% cleared by metabolism, 
predominantly in the liver to five inactive metabolites. The predominant 
pathways are hydroxylation of the phenyl ring and opening of the 
imidazoline ring following an initial reductive step with subsequent 
oxidative cleavage The major metabolite is P-hydroxyclonidine. The 
hydroxylated metabolites are subjected to secondary conjugation with 
sulphate or glucuronide prior to urinary excretion. 
EXCRETION  
70% of the dose, mainly in the form of unchanged parent drug is 
excreted (40 – 60%) in urine. So, the elimination t ½ of clonidine varies as 
a function of creatinine clearance.  
DOSAGE  
Oral   - 3-5µg/kg 
Intramuscular - 2 µg/kg 
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Intravenous - 1-3µg/kg 
Spinal   - 50 -100µg 
Epidural  - 1-2µg/kg 
Transdermal - 0.1-0.3 mg released per day 
PRECAUTIONS  
1. In patients with renal insufficiency, lower dose is needed. 
2. Sudden withdrawal of prolonged continuous epidural infusion produces 
hypertensive crisis. So it should be gradually discontinued over 2 to 4 
days. 
3. Use with caution in patients with cerebrovascular or coronary 
insufficiency. 
CONTRAINDICATIONS 
1. Known hypersensitivity to clonidine or components of the product. 
2. In patients with bradyarrhythmia or AV block. 
3. Patients with severe cardiovascular disease. 
4. Patients with cardiovascular / hemodynamic instability. 
INTERACTIONS 
1. Clonidine may potentiate the CNS - depressive effect of alcohol, 
barbiturates or other sedative drugs. 
2. Narcotics may potentiate the hypotensive effects of clonidine. 
36 
 
3. Tricyclic anti depressants may antagonize the hypotensive effects of 
clonidine. 
4. Concomitant administration of drugs with a negative chronotropic, 
dromotropic effect (beta blocker, digoxin) can cause or potentiate 
bradycardiac rhythm disturbances. 
USES 
1. Pre anaesthetic medication : 
Oral clonidine preanaesthetic medication (5µg/kg) 
(a) Blunts reflex tachycardia associated with direct laryngoscopy for 
intubation of trachea, (b) decrease intraoperative lability of blood 
pressure and heart rate, (c) decrease plasma catecholamine 
concentrations, and (d) dramatically decrease anaesthetic requirements 
for inhaled and injected drugs. Clonidine also attenuates the rise in 
intraocular pressure associated with laryngoscopy and intubation. 
2. Epidural block : Clonidine as sole agent or in combination with opioids 
or local anaesthetics to provide excellent analgesia in labour pain. 
Epidural clonidine is also indicated for the treatment of intractable pain, 
which is unresponsive to maximum does of oral opioid, as do patients 
with reflex sympathetic dystrophy and neuropathic pain. 
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3. Spinal anaesthesia: Clonidine combined with local anaesthetics 
improves the quality and duration of the block, minimize the tourniquet 
pain during lower limb surgery, and prevents shivering. 
4. Caudal anaesthesia: Clonidine combined with local anaesthetics 
increases the duration of anaesthesia and analgesia by 2 or 3 times 
without hemodynamic side effects. 
5. Peripheral nerve blocks: Clonidine prolongs the duration of anaesthesia 
and analgesia with local anaesthetics by two times in a dose of 75 to 
150 micro grams. 
6.  Bier’s Block: 150 microgram of clonidine enhances the tolerance of 
tourniquet. 
7.  It is also used in intra articular analgesia. 
8. Protection against perioperative myocardial ischemia; clonidine 
decreases myocardial ischemia, infarction and mortality following 
cardiovascular surgery. 
9. To treat hypertensive crises. 
10. Diagnosis of pheochromocytoma; 0.3 mg will decrease the plasma  
concentrations of catecholamine in normal patients but not in the 
presence of pheochromocytoma. 
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11. Treatment of shivering : Administration of clonidine,75µg IV stops 
shivering by inhibiting thermoregulatory control. 
12. Treatment of opioid and alcohol withdrawl syndrome. 
SIDE EFFECTS 
1. The most common side effects are sedation and xerostomia. 
2. Cardiovascular complaints are bradycardia, hypotension, and ECG 
abnormalities like junctional bradycardia, high degree AV block and 
arrhythmia are reported rarely. Occasionally requires treatment of 
bradycardia with I.V anticholinergics. Orthostatic hypotension occurs 
rarely. 
3.  Rebound hypertension; Abrupt discontinuation of clonidine can result 
in rebound hypertension as soon as 8 hours and as late as 36 hours after 
the last dose. Symptoms of nervousness, diaphoresis, headache, 
abdominal pain, and tachycardia often precede the actual increase in 
systemic blood pressure. Labetalol is useful in treatment of rebound 
hypertension. 
4. Skin rashes occurs rarely. 
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OVER DOSAGE 
There is no specific antidote for clonidine overdosage. Supportive 
measures like atropine, ephedrine, and i.v. fluids are required for 
treatment. 
          Yohimbine an alpha blocker partially reverses the analgesia and 
sedation but not the heart rate and blood pressure. 
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REVIEW OF LITERATURE 
1. Andrea casati et al, ANAESTHESIA ANALGESIA 2000, concluded 
small dose clonidine prolonged postoperative analgesia after sciatic 
femoral nerve block with ropivacaine. In this study 30 patients were 
randomly allocated in two groups, in which group A, 15 patients 
received 30 ml of 0.75% ropivacaine and in group B, 15 patients 
received 30 ml of 0.75% ropivacaine and 1µg/kg clonidine. There is no 
significant difference in the onset of sensory and motor blockade in both 
the groups. Duration of motor block was prolonged in ropivacaine - 
clonidine group. The mean time from block placement to first request 
for pain medication was shorter in ropivacaine (13.7 hrs) group when 
compared to ropivacaine - clonidine group (15.4 hrs). They concluded 
that 1µg/kg clonidine to 0.75% ropivacaine provided a 3 hour delay in 
first request of pain medication after hallux valgus repair with no 
clinically relevant side effects.  
2. Guido fanelli et al, ANAESTHESIA ANALGESIA 1998, A double 
blind comparison of ropivacaine, bupivacaine, and mepivacaine during 
sciatic  and femoral nerve blockade.  This study concluded that, for 
sciatic femoral block, 0.75% ropivacaine has an onset similar to that of 
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2% mepivacaine and the duration of postoperative analgesia between 
that of 0.5% bupivacaine  and 2% mepivacaine. 
3. Eledjam jj, Deschodt j et al, Canadian journal of anaesthesia1991; 
Brachial plexus block with bupivacaine; effects of added alpha-
adrenergic agonists: comparison between clonidine and epinephrine. In 
this study, 60 patients were randomly allocated in two groups, so that 30 
patients were randomly allocated in two groups. So that 30 patients 
received 150 micrograms of clonidine and 30 patients received 200 
micrograms of adrenaline. In clonidine group there is no difference in 
the onset of sensory blockade and motor blockade when compared to 
adrenaline group. Duration of motor blockade was prolonged in 
clonidine group (580.4 ± 38.7vs 290.6 ± 34.5 minutes) when compared 
to adrenaline group. The block produced with addition of clonidine was 
longer. (994.2 ± 34.2 Vs 728.3±3 5.8 minutes) and superior to that with 
adrenaline. The injection of clonidine into the brachial plexus sheath is 
an attractive alternative to epinephrine to prolong the duration of 
analgesia following upper limb surgery under conduction anaesthesia. 
4. Wolfgang Erlacher et al, Canadian Journal of anaesthesia 2001; 
Clonidine as an adjuvant for mepivacaine, ropivacaine and bupivacaine 
in axillary, perivascular brachial plexus block. The  study shows that the 
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addition of clonidine has a different impact on each of the three local 
anesthetics investigated in terms of onset and duration of block. 
Mepivacaine group has rapid onset compared to ropivacaine and 
bupivacaine group. The duration of motor block in the mepivacaine -  
clonidine group was 468 ± 62 mins vs mepivacaine group was 212± 47 
mins, The duration of motor block in ropivacaine- clonidine group was 
712 ± 82 mins vs ropivacaine group was 702 ±52 mins. The duration of 
motor block in bupivacaine-clonidine group was 972± 72 mins vs 
bupivacaine group was 728± 36mins. 
5. Brian M. Ilfeld et al, Anaesthesia Analgesia 2003; Continuous 
infraclavicular perineural infusion with clonidine and ropivacaine  
compared with ropivacaine alone. A randomized, double blinded, 
controlled Study. This study reported that clonidine is often added to 
long acting local anesthetic perineural infusions in an effort to improve 
post operative analgesia. 
6. Popping DM, Elian et al, Anaesthesiology 2009; clonidine as an 
adjuvant to local anaestheics for peripheral nerve and plexus block: 
Meta analysis of randomized trials. This study reported that the 
clonidine prolonged the duration of post operative analgesia by 122 
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minutes, sensory blockade by 74 minutes, and motor blockade by 41 
minutes. 
7. A.casati et al, sciatic nerve block with 0.5% levobupivacaine, 0.75% 
levobupivacaune and 0.75% ropivacaine: a double- blind randomized 
comparison. This study concluded that, 0.75% levobupivacaine provides 
a shorter onset time than 0.5% levobupivacaine and a longer duration of 
postoperative analgesia than both 0.5% levobupivacaine and 0.75% 
ropivacaine with reduced need for rescue analgesia after surgery. 
8. Gianluca Cappelleri et al, ANAEATHESIA ANALGESIA 2000, 
Evaluated the effect of the injection technique on the onset time and 
efficacy of femoral nerve block performed with 0.75% ropivacaine.      
A total of 30 patients undergoing arthroscopic knee surgery randomly 
allocated to receive femoral nerve block with 0.75% ropivacaine   by 
using either a single injection or multiple injection. They concluded the 
study, that searching for multiple muscular twitches shortened the onset 
time and improved the quality of femoral block with small volumes of 
0.75% ropivacaine. 
9. Pia di Benedetto et al, ANAESTHESIA ANALGESIA 2002, Compared 
the posterior popliteal and subgluteal continous sciatic nerve block for 
anaesthesia and acute postoperative pain management after foot surgery 
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60 patients were randomly assigned to either a subgluteal or popliteal 
group. Sciatic nerve block was performed with 20ml of 0.75% 
ropivacaine using either subgluteal or posterior popliteal approach and 
the placement of catheter afterwards. The catheter was connected to 
patient controlled analgesia pump to infuse 0.2% ropivacaine. They 
concluded that the subgluteal approach is as effective and safe as 
posterior popliteal approach for continous sciatic block and can be 
considered a useful alternative to anaesthesia and postoperative 
analgesia. 
10. Fanelli G et al ANAESTHESIOLOGY 1999, Studied the 
intraoperative and postoperative clinical properties of sciatic - femoral 
nerve block with either ropivacaine at different concentrations and with 
mepivacaine. Adult patients scheduled for foot and ankle surgery were 
randomized to receive combined sciatic-femoral block with 225 mg of 
either 0.5%,0.75% or 1% ropivacaine and 500mg of 2% mepivacaine. 
Onset time, adequacy of surgical anaesthesia, time to offset of nerve 
block and time until first postoperative requirement for pain were 
evaluated. The study concluded that 0.75% ropivacaine is the most 
suitable choice of local anaesthetic for combined sciatic- femoral nerve 
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block, providing an onset similar to mepivacaine and prolonged 
postoperative analgesia. 
11. Pia di Benedetto et al, ANAESTHESIA ANALGESIA 2001, 
evaluated the efficacy and acceptance of a new posterior subgluteal 
approach to the sciatic nerve with the classic posterior approach. 128 
patients undergoing foot orthopedic procedures were randomly allocated 
to receive either the classic posterior sciatic nerve block or a modified 
subgluteus posterior approach. In both groups, a proper sciatic 
stimulation was elicited at 0.5 mA, then 20 mL of 0.75% ropivacaine 
was injected. They concluded that this new subgluteal posterior 
approach to the sciatic nerve is an easy and reliable technique and can be 
considered an effective alternative to the more traditional Labat’s 
approach. 
12. Jacques E. Chelly et al, ANAESTHESIOLOGY 1999, Performed a 
new anterior approach to sciatic nerve block. Sciatic nerve blocks were 
performed in 22 patients. A line was drawn between the inferior border 
of the anterosuperior iliac spine and the superior angle of the pubic 
symphysis. Next, a perpendicular line bisecting the initial line was 
drawn and extended 8 cm caudal. The needle was inserted 
perpendicularly to the skin, and the sciatic nerve was identified at a 
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depth of 10.5 cm (9.5–13.5 cm; median and range) using a nerve 
stimulator and a 15-cm beveled insulated needle. After appropriate 
localization, either 30 ml mepivacaine, 1.5% or 15 ml mepivacaine, 
1.5%, plus 15 ml ropivacaine, 0.75%, injected. They concluded that this 
approach represents an easy and reliable anterior technique for 
performing sciatic nerve blocks. 
13. Pierre Beaulieu et al, ANAESTHESIA ANALGESIA 2006, 
compared the pharmacodynamics of equal concentrations of bupivacaine 
and ropivacaine in combined sciatic and femoral nerve blocks for 
patients undergoing knee arthroplasty. Fifty patients received 40 mL of 
either 0.5% bupivacaine or 0.5% ropivacaine, before induction of 
anesthesia. Loss and recovery of sensory and motor functions were 
recorded in the distribution of the femoral,  saphenous, common 
peroneal, and tibial nerves. Pain scores and morphine consumption over 
48 hours were also evaluated. They concluded that block  resolution is 
different between bupivacaine and ropivacaine when administered  for 
combined sciatic and femoral nerve blocks. 
14. Casati a, Magistris.L, et al, Minerva Anestesiol 2001, adding 
clonidine to ropivacaine for axillary approach of brachial plexus block 
provided prolonged analgesia without side effects of sedation and 
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cardiovascular homeostasis. In this study 30 patients were allocated to 
two groups for axillary approach of brachial plexus block. Group I 
received  20 ml of 0.75% ropivacaine and 1 µg/kg clonidine block. 
Group II received 20ml of 0.75% ropivacaine alone. Axillary block was 
performed with nerve locator. There was no difference in demography, 
degree of sedation, peripheral oxygen saturation and hemodynamic 
variables observed between the two groups. Readiness of surgery 
required 5-36 minutes with ropivacaine and 5-30 minutes in 
ropivacaine-clonidine mixture. The first postoperative analgesic request 
occurred after 13.8 hours in ropivacaine- clonidine group. 
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MATERIALS AND METHODS 
This study was conducted at Government Rajaji Hospital attached to 
Madurai medical college. The inclusion criteria being 60 patients of ASA 
grade I or II of either sex and age more than 20 years undergoing lower 
limb surgery (mostly orthopedic, vascular and general surgeries). 
        Patients with allergy to local anaesthetics, peripheral nerve injury, 
bleeding diathesis, local sepsis, patient refusal, contraindications to 
clonidine  and patients in whom the block was unsuccessful due to total 
failure of missed dermatomes which needed intravenous supplementation 
of  opioids or general anaesthesia were excluded from the study. 
           It was a double blinded study in which patients were randomly 
allocated into two groups, Group R-ropivacaine and Group RC– 
ropivacaine clonidine. Each group comprises of 30 patients, surgery was 
done under sciatic femoral nerve block. Preoperative investigations done 
were haemoglobin, blood sugar, urea, serum creatinine and urine albumin 
and sugar. 
PROCEDURE 
After ethical committee approval, informed consent was obtained 
from the patients. No premedication was given to the patients. Intravenous 
access was obtained, Anaesthesia machine checked, resuscitative 
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equipments and drugs were kept ready. Sciatic femoral block was 
performed by posterior Labats approach after confirmation with nerve 
stimulator. 
In GROUP R: Patients received 30 ml of 0.75% ropivacaine with 0.4 
ml normal saline. In this mixture 18 ml is given in sciatic nerve block   and 
12 ml in  femoral  nerve block. 
In GROUP RC: Patients received 30 ml of 0.75% ropivacaine with 
0.4 ml clonidine (60 microgram). In this mixture 18 ml is given in sciatic 
nerve block   and 12 ml in femoral nerve block. 
Care was taken so that the toxic doses of the local anaesthetics were 
not exceeded according to the weight of the patients. 
PARAMETERS OBSERVED 
1. Onset of analgesia 
Onset of analgesia was taken as abolishment of pin prick pain over the 
distribution of tibial and femoral nerve and was assessed every minute 
after the performance of the block. 
2. Onset of motor blockade : 
Onset of motor blockade was assessed every 3 minute after the block 
using four point scales 
0 – Normal power 
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1- Weakness but able to move leg 
2- Not able to move leg but able to move the toes 
3- Complete motor blockade 
Attaining a score of 2 was considered as the onset of motor Block 
3. Duration of surgery: 
4. Duration of motor Blockade: 
When (3) in the four point scale changes to (2) the motor blockade is 
said to reverse. The duration of motor block is noted from the time from 
scale (3) to scale (0) 
5. Duration of analgesia: 
The pain was assessed using visual analogue scale having 10 cm length 
numbered from 0 to 10. Patient was explained about the visual analogue 
scale as 0 – No pain and 10 the worst possible pain and was asked the 
score in visual analogue scale. 
The patients was observed every 30 minutes after the surgery was over 
till the motor block reverses and thereafter hourly for 6 hrs and 2 hourly 
for next 10 hrs. 
a. Duration of absolute pain free period: the post operative period during 
which the patient did not have pain (VAS -0). 
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b. Time at which VAS score is greater than 5 was noted and patient was 
given rescue analgesia as intramuscular NSAID (Injection – 
Diclofenac). 
c. Duration of post operative analgesia; the period of time after the 
surgery till the patient needs analgesic (VAS score more than 5). 
6. Vital parameters: 
Pulse rate, 
Blood pressure, 
SPO2. 
7. Ramsay sedation score: 
1. Awake & alert 
2. Sedated, responding to verbal commands 
3. Responding to physical stimulus 
4. Responding to moderate & severe physical stimulus 
5. Not arousable 
8. Side effects noted are 
Hypotension 
Bradycardia 
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DATA ANALYSIS 
The information collected regarding all the selected cases were 
recorded in a master chart. Data analysis was done with the help of 
computer using Epidemiological Information Package (EPI 2010) 
developed by centre for disease control, Atlanta. 
Using this software range, frequencies, percentages, means, standard 
deviations, chi square and  'p'  values were calculated. Kruskul Wallis chi-
square test was used to test the significance of difference between 
quantitative variables and Yate’s chi square test for qualitative variables. A 
'p' value less than 0.05 is taken to denote significant relationship. 
STATISTICAL ANALYSIS 
This study comprised of two groups. The patients in group R 
received ropivacaine 0.75% 30ml + 0.4ml normal saline. In group RC 
received 0.75% ropivacaine 30ml + 60 microgram of clonidine. 
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                  OBSERVATION AND RESULTS 
1. AGE 
Age group 
Ropivacaine 
group 
Ropivacaine & 
Clonidine group 
No % No % 
Upto 30 years 2 6.7 1 3.3 
31-40 years 5 16.7 3 10 
41-50 years 12 40 9 30 
51-60 years 10 33.3 14 46.7 
Above 60 1 3.3 3 10 
Total 30 100 30 100 
Range 25-65 years 30-65 years 
Mean 48 years 51 years 
SD 9.4 years 8.5 years 
‘p’ 
0.173   
NOT SIGNIFICANT 
 
Age distribution in the group R varied from 25-65 years with mean 
age of 48 years and standard deviation of (9.4). In group RC age varied 
from 30 to 60 years with mean value of 51 years and standard deviation of 
(8.5)   with a “p” value of 0.173 which is statistically insignificant.                                 
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2. SEX DISTRIBUTION 
 
Sex 
Ropivacaine 
group 
Ropivacaine & 
Clonidine group 
No % No % 
Male 20 66.7 23 76.7 
Female 10 33.3 7 23.3 
Total 30 100 30 100 
‘p’ 
0.5667 
Not significant 
 
In group R 20 patients were male 10 patients were female. In group 
RC 23 patients were male and 7 patients were female. There was no 
statistically significant difference in the sex composition of the two groups 
( “p” = 0.5667). 
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3. WEIGHT 
 
 
Parameter 
Weight ( in kgs) 
Ropivacaine 
group 
Ropivacaine & 
Clonidine group 
Range 40-70 45-70 
Mean 53.8 55.2 
SD 7.1 5.9 
‘p’ 
0.4329 
Not significant 
 
Weight of the patients in the group R  had a mean value of 53.8kgs 
with standard deviation of 7.1. In group RC had a mean value of 55.2 kgs 
with standard deviation of  5.9 with a “p” value of 0.4329 which is 
statistically insignificant. 
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4. ASA STATUS 
 
ASA  
Ropivacaine 
group 
Ropivacaine & Clonidine 
group 
No % No % 
I 8 26.7 8 26.7 
II 22 73.3 22 73.3 
Total 30 100 30 100 
‘p’ 
1.0 
Not significant 
 
In group R, 8 patients were ASA I and 22 patients were ASA II. In 
Group RC, 8 patients were ASA I and 22 patients were ASA II . Both the 
groups were comparable in respect to ASA classification with a “p” value 
of 1.0 which is statistically insignificant. 
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5. ONSET OF SENSORY BLOCK 
Onset of sensory 
block 
Group R (minutes) Group RC (minutes) 
Range 7-12 8-14 
Mean 9.93 10.53 
SD 1.6 1.8 
P 0.2605  Not significant 
Time taken for the onset of sensory blockade in group R varied from 
7 to 12  minutes  with standard deviation of 1.6 . In group RC it varied 
from 8 to 14 minutes with standard deviation of 1.8 with a “p” value of 
0.2605 which is statistically insignificant 
6. ONSET OF MOTOR BLOCK 
Onset of motor 
block 
Group R (minutes) Group RC (minutes) 
Range 10-15 10-18 
Mean 13.0 13.56 
SD 1.2 1.96 
‘p’ 0.1414 Not significant 
Onset of motor block varied from 10 to 15 minutes with standard 
deviation of 1.2. In group RC it varied from 10 to18 minutes with  
standard deviation of 1.96  with a “p” value of 0.1414 which is statistically 
insignificant. 
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7. DURATION OF SENSORY AND MOTOR BLOCK 
Parameter 
Duration ( in hours ) of 
Sensory block Motor block 
Ropivacaine 
group 
Ropivacaine 
& Clonidine 
group 
Ropivacaine 
group 
Ropivacaine 
& Clonidine 
group 
Range 10-13 14-16.5 9-11.8 11.5 – 14 
Mean 12.01 15.18 10.06 12.69 
SD 0.9 0.78 0.82 0.89 
‘p’ 
0.0001 
Significant 
0.0001 
Significant 
 
Duration of sensory block in the Ropivacaine group was 12.01 +0.9 
hours and in the Ropivacaine & clonidine group it was 15.18 +0.78 hours. 
Similarly duration of motor blocks in the two groups were 10.06 +0.82 
hours and 12.69 +0.89 hours.  
The differences between the two groups were statistically 
significant in respect to duration of sensory blockade with a “p” value of 
0.0001 and the duration of motor blockade with a “p” value of 0.0001. 
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8. DURATION OF SURGERY 
 
Parameter 
Duration of surgery(in hours) 
Ropivacaine 
group 
Ropivacaine & 
Clonidine 
group 
Range 0.58-1.15 0.67-1.5 
Mean 0.89 0.97 
SD 0.14 0.29 
‘p’ 
0.8607 
Not significant 
 
There was no significant difference in the duration of surgery in the 
two groups (p > 0.05). 
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9. DURATION OF ANALGESIA 
 
 
Parameter 
Duration of analgesia (in hours) 
Ropivacaine 
group 
Ropivacaine & 
Clonidine group 
Range 12-14 15-17.5 
Mean 12.87 16.07 
SD 0.63 0.68 
‘p’ 
0.0001 
Significant 
 
Duration of analgesia was significantly longer in the Ropivacaine - 
Clodinine group (16.07 +0.68 hours) than in the Ropivacaine group           
(12.87 +0.67 hours). ‘p’ value was 0.0001. The difference between the two 
groups were statistically significant 
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10. SEDATION SCORE 
TABLE – 10: SEDATION SCORE 
Sedation score 
Ropivacaine 
group 
Ropivacaine & 
Clonidine group 
No % No % 
1 30 100 7 23.13 
2 - - 23 76.7 
Total 30 100 30 100 
 
All the cases in the Ropivacaine group had a sedation score of 1. But 
only 7 cases in Ropivacaine & Clodinine group had a score of 1 and the 
remaining 23 had a score of 2. 
The difference between the two groups is statistically significant     
with a “p” value of 0.0001. 
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11. HEART RATE 
 
Heart rate at 
Heart rate ( Mean +SD) for 
‘p’ Significance Ropivacaine 
group 
Ropivacaine & 
Clodinine group 
0 minute 83.9 +11.9 83.2 +12.2 0.7159 Not significant
5 minutes 87.1 +11.9 90.5 +13.2 0.1336 Not significant
10 minutes 83.1 +11.8 90.7 +13.3 0.0604 Not significant
20 minutes 81.5 +11.6 88.2 +12.5 0.0577 Not significant
30 minutes 81.0 +10.7 84.8 +12.7 0.1402 Not significant
40 minutes 80.9 +10.1 83.3 +12.6 0.4408 Not significant
50 minutes 80.5 +10.8 81.7 +12.0 0.5581 Not significant
60 minutes 79.4 +10.0 80.9 +11.7 0.5289 Not significant
120 minutes 79.1 +9.8 81.0 +11.8 0.4497 Not significant
180 minutes 79.1+ 9.6 80.5 +12.0 0.6617 Not significant
240 minutes 78.7 +9.6 79.9 +11.8 0.6176 Not significant
300 minutes 79.1 +9.2 79.6 +11.7 0.9467 Not significant
 
 There were no statistically significant differences in the mean heart 
rates at all time intervals. 
 
 
 
 
CHANGES IN HEART RATE
85
90
95
60
65
70
75
80
H
ea
rt
 r
at
e
50
55
0
min.
5 mts 10
mts
20
mts
30
mts
40
mts
50
mts
60
mts
120
mts
180
mts
240
mts
300
mts
R GROUP RC GROUP  
63 
 
13. SYSTOLIC BLOOD PRESSURE 
 
 
SBP at 
SBP values ( Mean +SD) for 
‘p’ Significance Ropivacaine 
group(mmhg) 
Ropivacaine & 
Clonidine 
group(mmhg) 
0 minute 122.3 +10.7 125.5 +9.7 0.2625 Not significant 
5 minutes 129.5 +8.8 129.1 +9.5 0.8928 Not significant 
10 minutes 128.7+9 129 +9.3 0.7429 Not significant 
20 minutes 126.8 +10.1 126.7 +9.1 0.9583 Not significant 
30 minutes 124.7+ 10.1 125.1+ 10 0.749 Not significant 
40 minutes 123.8 +10.0 124.9 +9.7 0.7042 Not significant 
50 minutes 123.6 +10.3 124.7 +10.1 0.6651 Not significant 
60 minutes 122.9 +10.2 124.9 +9.8 0.4923 Not significant 
120 minutes 122.0 +10.5 125 +9.6 0.3207 Not significant 
180 minutes 122.1 +10.1 125.2 +9.4 0.2726 Not significant 
240 minutes 121.8 +10.5 125.3 +9.7 0.2252 Not significant 
300 minutes 121.8 +10.5 125.5 +9.6 0.1778 Not significant 
 
Mean systolic blood pressure of the two groups did not have a any 
significant difference at all time intervals. 
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14. DIASTOLIC BLOOD PRESSURE 
 
DBP at 
DBP values ( Mean +SD) for 
‘p’ Significance Ropivacaine 
Group (mmhg) 
Ropivacaine & 
Clodinine 
Group (mmhg)
0 minute 77.9 +6.7 75.6+ 5 0.1273 Not significant 
5 minutes 81.1 +7.3 79.1 +6.3 0.3564 Not significant 
10 minutes 80.9 +6.3 78.9 +6.3 0.3287 Not significant 
20 minutes 80.3 +6.5 78.5 +6.7 0.3797 Not significant 
30 minutes 80.1 +6.6 78.2 +6.8 0.3815 Not significant 
40 minutes 80.0 +6.2 78.4 +7 0.3944 Not significant 
50 minutes 79.9 +6.3 78.5 +6.9 0.4543 Not significant 
60 minutes 79.8 +6.2 77.9 +6.6 0.3402 Not significant 
120 minutes 79.8 +6.2 77.6 +6.6 0.2607 Not significant 
180 minutes 79.7 +6.1 77.0 +6.7 0.1887 Not significant 
240 minutes 79.7 +6.3 76.8 +6.8 0.144 Not significant 
300 minutes 79.7 +6.3 76.7 +6.8 0.0949 Not significant 
There were no statistically significant differences in the mean 
diastolic blood pressures of two groups at all time intervals.  
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  15. SATURATION 
                     
 
Parameter 
SPO2 % 
Ropivacaine 
group 
Ropivacaine & 
Clonidine group 
Range 98.4-100 98.6-99.9 
Mean 99.25 99.31 
SD 0.54 0.45 
‘p’ 
0.7768 
Not Significant 
                      
Differences in the mean SpO2 values of the two groups were 99.25 
and 99.31 with a “p” value of 0.7768 which is statistically insignificant. 
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                                DISCUSSION 
Alpha- 2agonist like clonidine assumes greater importance as 
anaesthetic adjuvant and analgesic. Its primary effect is symphatholytic. It 
reduces peripheral norepinephrine release by stimulation of prejunctional 
inhibitory alpha-2 adrenoreceptors. It inhibits central neural transmission 
in the dorsal horn by presynaptic and postsynaptic mechanism and directly 
in spinal preganglionic sympathetic neurons. Tradionally it was used as 
antihypertensive drug, but uses based on sedative, anxiolytic and analgesic 
properties are being developed.  
In this study 60 microgram of clonidine added to combined sciatic 
femoral block has showed no statistically significant difference between 
the two groups as regard to age, sex, weight and ASA status. Onset of 
sensory and motor blocks occurred in 9.93 +1.6 minutes and 13 +1.2 
minutes respectively in the ropivacaine group. Onset of sensory and motor 
block occurred in 10.53 + 1.8 minutes and 13.56 + 1.96 minutes in the 
ropivacaine clonidine group. The addition of clonidine has not shown 
much effect on the onset of sensory and motor block. Duration of surgery 
was comparable in both groups. 
Mean duration of sensory block in ropivacaine group was 12.01± 0.9 
hours and in ropivacaine clonidine group was 15.18± .78 hrs. The 
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difference between the two groups was statistically significant with a p 
value of  0.0001 (P<0.05). 
These results correlates with studies conducted by casti et all, in which the 
duration of sensory block was 10-13 hours in ropivacaine group and it was 
12-16 hours in ropivacaine clonidine group.   
Mean duration of motor block in ropivacaine group was 10.06 +0.82 
hours and in ropivacaine clonidine group was 12.69 ±0.89 hours. The 
difference between the two groups was statistically significant with a p 
value of 0.0001 (P<0.05). These results correlates with studies conducted 
by casti et all, in which the duration of motor block was 8-14 hours in 
ropivacaine group and it was 8.5-22 hours in ropivacaine clonidine group. 
The addition of clonidine to local anaesthetic solution has significantly 
prolonged the duration of sensory and motor blockade. This is because 
clonidine blocks the conduction of C and A gamma fibres and increase the 
potassium conductance in isolated neurons and intensifies the conduction 
of local anesthetics.  
Duration of analgesia was significantly longer in the ropivacaine -
clodinine group (16.07 +0.68 hours) than in the ropivacaine group (12.87 
+0.67 hours). The difference between the two groups was statistically 
significant with a p value of .0001<(p0.05). These results correlates with 
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studies conducted by casti et all, in which duration of analgesia was 11.8-
14.5 hours in ropivacaine group and it was 13.5-17.8 hours in ropivacaine 
clonidine group. Clonidine has been demonstrated to inhibit the action 
potential of A- alpha and C fibres in desheathed sciatic nerves. The α2 
adrenergic receptors activated by clonidine are located on primary afferent 
terminals, neurons in the superficial laminae of the spinal cord and in brain 
stem nuclei implicated in analgesia. Inhibition of noradrenaline release, 
mediated by an interaction with α2 adrenergic presynaptic receptors is 
responsible for the enhancing effect of the peripheral administration of 
clonidine. Peripheral antinociception induced by clonidine has also been 
related to an α2- adrenorecptor mediated local release of enkephalin like 
substance.  
The sedation score in both groups are noted.  The sedation score in 
ropivacaine group was 1.0, in ropivacaine clonidine group was 2.4± 0.5. 
The sedation score between the two groups was statistically significant 
with a “p” value of 0.0001.  In clonidine group since the sedation score 
was not more than 3, the respiratory function was not compromised. 
 In this study, no significant difference was observed with respect to 
the pulse rate, systolic and diastolic blood pressure and saturation.     
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By performing sciatic femoral nerve block for lower limb surgeries, 
adequate postoperative analgesia can be given. Pain is an important factor 
for any cardiovascular disease patients undergoing surgery in the lower 
limb. Postoperative pain produces tachycardia, which could be deleterious 
to the patients. Hence sciatic femoral nerve block can be performed for 
these cardiovascular disease and high risk patients that can provide 
prolonged postoperative analgesia and comfort to the patient. . Clonidine 
like adjuvants will prolong the duration of postoperative analgesia. Low 
dose of clonidine produces sedation without any respiratory compromise. 
Hence the addition of low dose of clonidine in nerve blocks will provide 
sedation and prolongation of postoperative analgesia without any systemic 
side effects. 
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SUMMARY 
60 Patients of ASA grade I or II undergoing upper limb surgeries 
were randomly assigned into two groups, groups R and RC. 
Surgery was done under sciatic femoral nerve block through Labats 
approach. The patients in group R received 30 ml at 0.75% Ropivacaine 
and 0.4 ml Normal saline. In group RC received 30 ml at 0.75% 
Ropivacaine and 60 micrograms clonidine. In this 30ml mixture, 18 ml 
given in sciatic nerve block and 12 ml given in femoral nerve block. 
Parameters observed were time of onset of sensory and motor block, 
duration of motor blockade, and sensory blockade, duration of post 
operative analgesia, sedation score and side effects. 
This study shows that 
1. There is no significant difference  in the onset of sensory blockade in 
ropivacaine clonidine group when compared to ropivacaine 
2. There is no significant difference  in the onset of motor blockade in 
ropivacaine clonidine group when compared to ropivacaine 
3. Duration of sensory block in the ropivacaine group was 12.01 hours and 
in the ropivacaine clonidine group was 15.18 hours. The addition of 
clonidine to ropivacaine increases the duration of sensory blockade  by 
184 minutes,when compared to ropivacaine alone. 
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4. Duration of motor block in ropivacaine was 10.06 hours and in 
ropivacaine clonidine was 12.69 hours. The addition of clonidine to 
ropivacaine increases the duration of motor blockade by 157 minutes. 
5. Duration of analgesia in ropivacaine group was 12.87 hours and in the 
ropivacaine clonidine group was 16.07 hours. The addition of clonidine 
to ropivacaine significantly prolongs the duration of post operative 
analgesia by 192 minutes when compared to  ropivacaine alone. 
6.  In ropivacaine group the mean intraoperative sedation score was 1.In 
clonidine group, the mean intraoperative sedation score was 1.76 which 
did not compromise respiratory function. 
7. There were no side effects like hypotension and bradycardia in 
clonidine group. 
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CONCLUSION 
The addition of clonidine to ropivacaine in sciatic femoral nerve block  
shows no difference in the onset of sensory and motor blockade but 
prolongs the duration of both sensory and motor blockade and post 
operative analgesia, when compared to ropivacaine alone. 
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PROFORMA 
TO EVALUATE THE EFFECTIVENESS OF CLONIDINE AS AS 
AN ADJUVANT TO ROPIVACAINE IN SCIATIC FEMORAL NERVE 
BLOCK FOR LOWER LIMB SURGERY 
Name  :                                                Age:         Sex:     ASA status: 
IP No  :                                         Weight: 
Diagnosis  : 
Surgery  : 
Investigations  
Hb %:  
Urine Albumin: 
              Sugar: 
Blood sugar: 
Blood urea: – mg% 
Serum creatinine: mg% 
Group R – 30 ml of 0.75% Ropivacaine + 0.4 ml NS 
Group RC – 30 ml of 0.75% Ropivacaine + 150 microgram clonidine 
OBSERVATIONS 
Onset of sensory blockade      : 
Onset of motor blockade         : 
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Duration of sensory blockade  : 
Duration of motor blockade     : 
Duration of surgery                    : 
Duration of analgesia                 : 
Side effects 
Hypotension     :  yes/no          Bradycardia: yes/no 
Motor block 
       0 – Normal power  
       1 - Paresis but able to move arm 
       2 - Not able to move arm but able to move fingers 
       3 - Complete motor blockade. 
VAS (Visual analog scale): 
Sedation score: Ramsay sedation score 
      1. Awake and alert 
      2. Conscious and oriented 
      3. Sedated responding to verbal stimulus 
      4. Responding to mild physical stimulus 
      5. Responding to moderate and severe physical stimulus 
      6. Arousable. 
Sl.
No
Name
Age/
Sex
IP 
NO
Wt    
in Kg
ASA 
Status
Diagnosis & Procedure
onset of 
Sensory  
block in 
Mins.
   onset of 
Motor 
block in 
Mins
Duration 
of  
sensory 
block in 
Hrs.
Duration 
of Motor  
block in 
Hrs.
Duration   
of 
analgesia
Duration 
of surgery 
in Hrs
Sedati
on 
score
Side 
effects
1 Indumathy 54/F 73451 55 II Right diabetic foot‐BK Amputation 6 8 12.5 10 13.1 0.75 1 nil
2 Rajappan 46/M 6071 60 II PVOD left foot‐ BK Amputation 8 12 12.8 10.5 13.5 1 1 nil
3 Arumugam 25/M 46682 50 I Metatarsal fracture ‐k wire fixation 7 10 11 9 12.2 1 1 nil
4 Arumugam 60/M 6157 55 II Left diabetic foot‐BK Amputation 8 9 12.5 10.5 13.5 0.833333 1 nil
5 Pandiammal 50/F 2756 45 II Right diabetic foot‐BK Amputation 6 10 12.8 10.8 14 1 1 nil
6 Murugan 25/M 92448 60 I Left diabetic foot‐BK Amputation 8 10 12.8 10 13 1.15 1 nil
7 Ravichandran 40/M 44417 60 II Right diabetic foot‐BK Amputation 10 12 12 10 12.8 1 1 nil
8 Jeyalakshmi 45/F 48676 50 II Right diabetic foot‐BK Amputation 12 14 12.5 11 13 1.15 1 nil
9 Ramalingam 50/M 32245 50 II PVOD left foot ‐BK Amputation 8 12 12.8 10.5 13.2 1 1 nil
10 Karuppiah 55/M 24951 60 II Left diabetic foot‐BK Amputation 8 10 11 9 12 0.75 1 nil
11 Suraj 36/M 42780 50 I PVOD right foot ‐BK Amputation 9 14 12 11 12.5 0.833333 1 nil
12 Kumar 44/M 44082 70 II Right diabetic foot‐BK Amputation 12 14 12.5 10 13 0.75 1 nil
13 Chinnakannu 60/M 4908 50 II PVOD right leg‐BK Amputation 10 12 10 9 12 0.83333 1 nil
14 Sonnaiammal 55/F 39214 60 II PVOD right leg‐BK Amputation 8 10 12.5 10 12.2 1 1 nil
15 Raju 40/M 56811 60 I Right diabetic foot‐BK Amputation 10 14 12.8 11 13.5 0.75 1 nil
16 Palaniappan 56/M 61259 45 II Left diabetic foot‐BK Amputation 8 12 13 11 13.5 0.83333 1 nil
17 Tamilarasi 50/F 19362 50 I Left diabetic foot‐BK Amputation 7 10 11 9 12.5 1 1 nil
18 Ponnuthai 60/F 19711 40 II Right diabetic foot‐BK Amputation 8 9 12.5 10.5 13 0.83333 1 nil
19 Ganapathi 56/M 70576 60 II Metatarsal fracture ‐k wire fixation 8 10 12.8 10.8 14 1 1 nil
20 Muthukrishnan 40/M 6948 62 I Lateral malleolus fracture‐ k‐wire fixation 10 12 10 9 12 0.83333 1 nil
21 Raja 48/M 78910 55 II Non healing ulcer‐rt foot‐BK Amputation 12 14 12.5 10 13 0.83333 1 nil
22 Mohammed ali 50/M 41505 65 II Cellulitis right foot‐BK Amputation 10 12 12 10 12.5 1 1 nil
23 Indirani 38/F 76608 42 I Left diabetic foot‐BK Amputation 9 14 11.5 9 12 0.75 1 nil
24 krishnaveni 52/F 57682 50 II PVOD right leg‐BK Amputation 8 10 12.5 11 13.5 1 1 nil
25 Balu 44/M 22526 50 II Right diabetic foot‐BK Amputation 8 12 12.5 11.8 13.8 0.75 1 nil
26 Ganesan 46/M 70770 50 II PVOD right leg‐ BK Amputation 10 12 10 9 12 0.83333 1 nil
27 Sundaram 65/M 2501 50 II PVOD left leg‐ BK Amputation 12 14 12 10 12.8 0.583333 1 nil
28 Subramanian 50/M 14389 45 I Crushinjury right foot‐ stabilisation 7 9 11 9 12 0.75 1 nil
29 Pandian 48/M 32385 50 II Left diabetic foot‐BK Amputation 9 13 12 9 13 0.833333 1 nil
30 Dhanalakshmi 52/F 36907 55 II Right diabetic foot‐BK Amputation 10 12 12.5 10.5 13 1 1 nil
GROUP ‐ ROPIVACAINE 
S.No. GROUP 0 MIN 5 MIN 10 MIN 20 MIN 30 MIN 40 MIN 50 MIN 60 MIN 120 MIN 180 MIN 240 MIN 300 MIN
1 R 90 95 96 92 90 84 86 84 84 84 84 84
2 R 110 112 114 112 110 106 104 102 102 100 102 100
3 R 100 110 98 96 94 94 96 94 92 92 92 92
4 R 78 75 74 74 76 74 72 72 70 72 70 72
5 R 84 82 84 82 80 78 78 76 74 72 74 74
6 R 114 116 110 108 106 104 104 102 100 99 98 98
7 R 114 108 104 104 102 102 104 100 98 98 98 98
8 R 82 86 78 76 78 80 82 80 78 78 78 78
9 R 88 94 96 92 90 90 90 88 88 86 86 84
10 R 84 88 88 84 84 82 82 80 82 84 84 84
11 R 74 80 78 76 77 76 74 74 72 76 72 72
12 R 84 80 78 76 76 76 74 72 74 74 72 72
13 R 78 74 72 72 76 76 76 78 76 72 72 72
14 R 74 80 70 68 68 68 66 68 68 68 66 66
15 R 88 84 82 82 80 80 84 82 78 80 80 80
16 R 78 84 78 74 72 74 72 70 72 70 72 78
17 R 80 86 78 80 76 76 74 76 76 76 74 74
18 R 78 80 78 76 74 76 74 72 70 70 72 72
19 R 82 86 80 78 76 77 78 79 80 84 80 80
20 R 86 90 87 89 88 88 88 86 84 84 82 82
21 R 78 84 80 76 78 75 74 72 74 72 70 70
22 R 80 84 78 78 80 82 76 77 78 80 78 78
23 R 72 78 76 74 72 77 78 78 76 79 72 72
24 R 74 78 72 70 70 72 68 66 68 70 72 72
25 R 76 80 76 74 75 76 75 76 75 74 72 72
26 R 77 80 76 75 75 74 72 74 72 70 72 74
27 R 70 74 72 70 72 76 78 74 72 72 72 74
28 R 80 84 78 76 76 74 74 72 74 72 78 78
29 R 70 74 68 69 70 67 68 67 69 70 72 74
30 R 94 106 94 92 90 94 94 92 97 96 94 96
GROUP ROPIVACAINE PULSE RATE CHART(beats/min)
S.No GROUP 0 MIN 5 MIN 10 MIN 20 MIN 30 MIN 40 MIN 50 MIN 60 MIN 120 MIN 180 MIN 240 MIN 300 MIN
1 R 130 128 130 130 130 130 130 130 130 130 130 130
2 R 140 146 144 140 140 140 140 140 140 140 140 140
3 R 120 130 130 128 120 120 120 120 120 120 118 118
4 R 120 120 124 120 118 118 120 120 120 120 120 120
5 R 130 130 134 134 128 128 128 126 120 128 128 128
6 R 140 140 138 138 138 138 140 140 140 140 140 140
7 R 120 124 124 128 128 128 128 120 120 120 120 120
8 R 120 124 120 120 120 120 118 118 118 118 120 120
9 R 130 130 130 128 128 128 130 130 130 130 130 130
10 R 120 130 130 128 128 126 120 120 120 118 118 118
11 R 110 120 116 114 112 110 110 110 110 110 110 110
12 R 110 118 120 120 116 114 112 110 110 108 106 106
13 R 120 130 130 120 118 118 116 116 114 114 110 110
14 R 130 130 130 128 126 124 128 128 128 126 124 124
15 R 100 120 116 104 104 102 102 102 100 104 104 104
16 R 110 120 120 120 120 120 116 114 114 114 112 112
17 R 130 140 130 128 128 126 126 124 124 122 122 122
18 R 130 140 140 138 136 130 130 130 134 130 130 130
19 R 120 128 128 128 126 126 126 126 122 120 120 120
20 R 110 118 118 120 120 1220 120 116 110 116 116 116
21 R 140 146 148 150 144 144 144 142 140 140 142 142
22 R 120 130 130 130 130 128 128 128 124 124 124 124
23 R 130 136 136 136 136 132 130 130 130 130 130 130
24 R 130 134 134 134 132 132 130 130 130 130 130 130
25 R 110 120 120 120 110 110 110 112 112 112 110 110
26 R 120 128 126 126 126 124 126 124 120 120 120 120
27 R 110 116 116 110 110 110 110 110 110 110 110 110
28 R 120 130 130 118 118 118 120 120 120 120 120 120
29 R 140 148 148 146 140 140 140 140 140 140 140 140
30 R 110 130 120 120 110 110 110 110 110 110 110 110
 GROUP ROPIVACAINE SYSTOLIC BLOOD PRESSURE(mmhg)
S.No GROUP 0 MIN 5MIN 10 MIN 20 MIN  30MIN 40 MIN 50 MIN 60 MIN 120 MIN 180 MIN 240 MIN  300 MIN
1 R 80 80 80 78 78 78 78 76 76 76 78 78
2 R 80 84 80 80 78 80 80 80 80 80 80 80
3 R 70 70 70 70 70 70 70 70 70 70 70 70
4 R 80 82 84 80 82 80 78 78 78 78 78 78
5 R 80 80 80 78 78 78 78 78 78 78 78 80
6 R 80 80 80 80 80 80 80 82 82 80 80 80
7 R 90 96 88 88 88 88 90 90 90 90 90 90
8 R 80 80 80 80 76 76 78 76 76 76 76 76
9 R 72 74 74 74 74 74 74 76 76 76 76 76
10 R 70 76 76 76 74 74 74 74 74 74 74 74
11 R 80 82 82 82 82 82 82 82 82 80 82 82
12 R 70 74 74 72 72 72 72 72 72 70 70 70
13 R 70 76 76 76 76 76 78 78 8 78 78 78
14 R 80 84 84 82 82 82 82 82 80 80 80 80
15 R 70 70 70 70 70 70 70 70 70 74 74 74
16 R 80 80 80 80 82 84 84 84 86 86 86 86
17 R 82 80 80 78 76 78 78 78 78 78 76 76
18 R 80 84 84 84 84 82 80 82 82 80 80 80
19 R 90 96 94 98 98 94 94 94 94 94 94 94
20 R 70 70 76 76 76 76 76 76 76 76 78 78
21 R 90 94 94 92 92 92 92 90 90 90 90 90
22 R 70 78 78 78 78 78 78 78 77 76 76 76
23 R 80 84 84 84 84 86 86 84 84 84 84 84
24 R 84 88 90 90 90 90 90 90 90 90 90 90
25 R 70 74 76 76 76 76 76 76 78 78 78 78
26 R 80 88 88 84 84 80 80 80 80 80 80 80
27 R 70 76 78 78 78 78 76 76 76 76 74 74
28 R 80 84 84 82 82 82 80 80 80 80 80 80
29 R 70 76 74 74 74 74 74 72 72 72 70 70
30 R 88 94 90 90 90 90 90 90 90 90 90 90
GROUP ROPIVACAINE DIASTOLIC BLOOD PRESSURE(mmhg)
S.
No
Name
Age/
Sex
IP NO
Wt 
in Kg
ASA  Diagnosis & Procedure
onset of 
Sensory  
block in 
Mins.
   onset of 
Motor 
block in 
Mins
Duration 
of  
sensory 
block in 
Hrs.
Duration 
of Motor  
block in 
Hrs.
Duration   
of 
analgesia
Duration 
of surgery 
in Hrs
Sedatio
n score
Side 
effects
1 Ayyavoo 50/M 15327 62 I Left diabetic foot‐BK Amputation 10 12 15.8 12 16.5 1.5 2 nil
2 Periammal 52/F 33177 55 II Left diabetic foot‐BK Amputation 9 14 15.5 11.8 16 0.75 1 nil
3 Vinayagham 58/M 38890 65 I Crush injury right foot‐k‐wirestabilisation 10 14 16 14 17.5 1.5 2 nil
4 Rajendran 65/M 44664 50 II Non healing ulcer‐rt foot‐BK Amputation 12 14 15.5 12 16.2 0.75 2 nil
5 Jayapal 55/M 87759 60 II Right diabetic foot‐BKAmputation 8 10 15 13 16 0.75 2 nil
6 Muthusamy 60/M 5695 50 II Left diabetic foot‐BK Amputation 9 13 14 11.5 15.2 1 2 nil
7 Solaimalai 52/M 37656 60 II Right diabetic foot‐BKAmputation 12 15 15 12 16.2 0.666667 2 nil
8 Perumal 48/M 104962 70 I Left diabetic foot‐BK Amputation 10 15 14 11.5 15 1.5 2 nil
9 Chellaiya 62M 678037 50 II Right diabetic foot‐BK Amputation 14 18 16.5 14 17 1 2 nil
10 Veerayee 42/F 36141 55 I Bimalleolar fracture‐ k wire fixation 12 14 15.5 12 16.5 0.75 2 nil
11 Nataraj 55/M 75978 50 II PVOD left foot ‐BK amputation 8 10 15 13 15.2 0.666667 1 nil
12 Occhammal 56/F 44070 60 II Left diabetic foot‐BK Amputation 9 12.8 14 11.5 15 1 2 nil
13 Raju 60/M 41814 60 II PVOD‐rightt foot ‐BK amputation 10 12 15.8 12 16.8 1.5 2 nil
14 Poomari 55/F 61918 60 II Right diabetic foot‐BK Amputation 12 14 15 13 16.2 1 2 nil
15 Manikkam 52/M 72791 50 II PVOD right leg‐BK Amputation 14 15 16.5 14 16.8 1.25 1 nil
16 Nataraj 34/M 101798 50 I PVOD right leg‐BK Amputation 10 12 15.5 12.5 16.5 1.5 1 nil
17 Pandi 50/M 38346 60 II Right diabetic foot‐BK Amputation 9 14 15 11.8 15.8 0.75 2 nil
18 Moideen beevi 55/F 38694 55 II Left diabetic foot‐BK Amputation 10 12 16 14 17.2 1 2 nil
19 Muthusamy 60/M 56957 50 II Left diabetic foot‐BK Amputation 12 14 15.5 12 16.5 0.75 1 nil
20 Bose 45/M 25340 60 II Right diabetic foot‐BKAmputation 10 15 14 11.5 15 1.25 2 nil
21 Shanmugam 48/M 46613 50 II Metatarsal fracture ‐k wire fixation 8 10 14 13.5 15.8 1 2 nil
22 Shanthi 30/F 38890 50 I Lateral malleolus fracture‐ k wire fixation 9 12 14 12 15.5 0.75 1 nil
23 Irulan  52/M 106427 55 II Non healing ulcer‐rt foot‐BK Amputation 12 15 15 13 16.2 0.666667 2 nil
24 Vellaipandi 40/M 40125 50 I Cellulitis right foot‐BK Amputation 12 14 15.5 12.5 15.2 0.75 1 nil
25 Perumal 48/M 25104 55 II Left diabetic foot‐BK Amputation 8 11 15 13 15.5 0.666667 2 nil
26 Perumal 42/M 104962 60 II PVOD right leg‐BK Amputation 10 14 15.8 14 15.8 0.75 2 nil
27 Subburaj 65/M 36141 50 II Right diabetic foot‐BK Amputation 14 18 16.5 14 17 1 2 nil
28 Kaliammal 50/F 13917 45 I Left diabetic foot‐BK Amputation 12 15 15 13 16.2 0.75 2 nil
29 Shanmugam 40/M 45514 50 II PVOD left foot‐BK Amputation 11 14 15 13 16 1 2 nil
30 Arumugam 52/M 15065 60 II Right diabetic foot‐BK Amputation 10 14 14.5 13.5 15.8 1 2 nil
GROUP ‐ ROPIVACAINE CLONIDINE
S.No GROUP 0 MIN 5 MIN 10 MIN 20 MIN 30 MIN 40 MIN 50 MIN 60 MIN 120 MIN 180 MIN 240 MIN 300 MIN
1 RC 90 100 86 85 82 82 80 82 82 82 80 80
2 RC 110 116 102 100 106 104 100 96 96 96 96 94
3 RC 78 84 86 88 82 80 82 84 84 82 80 84
4 RC 84 90 94 94 84 86 86 86 86 84 84 84
5 RC 114 120 120 118 116 116 112 110 110 110 110 110
6 RC 114 124 120 120 120 118 112 112 112 114 112 112
7 RC 82 90 90 90 88 88 86 84 84 82 82 80
8 RC 72 90 88 88 86 88 84 80 84 80 78 78
9 RC 84 98 100 96 86 86 86 84 84 84 84 84
10 RC 78 90 94 76 78 78 78 78 80 80 82 84
11 RC 74 86 82 80 76 72 72 72 72 72 72 70
12 RC 88 100 112 96 90 90 88 88 88 88 90 88
13 RC 80 90 96 96 88 82 82 82 82 80 82 82
14 RC 78 88 90 92 80 80 78 78 78 78 76 76
15 RC 100 110 112 102 102 96 96 96 96 96 94 94
16 RC 78 82 86 80 80 78 78 76 76 76 78 78
17 RC 80 90 94 80 78 78 78 78 76 76 76 76
18 RC 86 90 90 92 88 88 84 82 82 80 78 78
19 RC 78 84 84 84 78 74 74 74 74 76 74 72
20 RC 72 80 80 76 72 70 68 68 68 66 68 68
21 RC 72 72 70 72 72 72 70 68 68 68 68 66
22 RC 76 80 82 82 74 74 70 68 66 66 66 66
23 RC 78 82 88 88 84 80 80 78 78 76 72 72
24 RC 72 70 68 68 66 66 66 64 66 66 64 66
25 RC 80 84 86 86 86 82 80 78 78 78 78 78
26 RC 79 82 82 86 78 74 72 70 72 72 72 70
27 RC 69 74 68 66 68 66 62 64 64 62 62 62
28 RC 93 92 94 92 90 88 86 86 86 86 86 84
29 RC 87 96 100 98 94 92 92 90 90 90 84 82
30 RC 70 80 76 74 72 72 70 70 68 68 70 70
GROUP ROPIVACAINE CLONIDINE PULSE RATE CHART(beats/min)
S.No GROUP 0 MIN 5 MIN 10 MIN 20 MIN 30 MIN 40 MIN 50 MIN 60 MIN 120 MIN 180 MIN 240 MIN 300 MIN
1 RC 130 13 128 128 126 126 128 128 126 126 126 126
2 RC 120 130 126 118 116 116 114 116 116 118 118 118
3 RC 120 120 118 116 120 120 120 120 120 120 120 120
4 RC 126 130 130 130 128 128 128 128 128 128 128 128
5 RC 130 134 140 130 130 130 130 130 130 132 132 132
6 RC 140 140 140 138 138 140 140 140 140 140 140 140
7 RC 110 120 110 110 100 110 106 110 114 116 118 120
8 RC 120 120 120 118 120 120 120 120 120 1220 110 110
9 RC 110 120 120 120 110 110 110 110 110 110 110 110
10 RC 130 136 140 138 130 130 130 130 130 130 130 130
11 RC 120 120 130 118 120 120 120 120 122 120 120 124
12 RC 130 140 134 130 130 130 130 130 130 130 130 130
13 RC 120 130 128 128 124 120 120 120 120 120 120 120
14 RC 130 138 138 138 130 130 130 130 130 130 130 130
15 RC 140 144 146 140 140 140 140 138 138 138 138 138
16 RC 110 118 118 118 120 110 110 110 110 110 110 110
17 RC 140 146 140 140 140 140 140 140 140 140 140 140
18 RC 130 132 132 130 130 130 130 130 130 130 130 130
19 RC 130 134 134 130 130 130 130 130 130 130 130 130
20 RC 140 140 140 140 140 138 138 140 140 140 140 140
21 RC 120 120 120 120 120 120 120 120 120 120 120 120
22 RC 120 124 124 118 118 116 118 120 120 120 120 120
23 RC 110 120 120 120 110 110 110 110 110 110 110 110
24 RC 130 134 134 130 128 128 128 128 128 128 130 130
25 RC 120 120 120 118 118 118 116 116 116 116 120 120
26 RC 120 124 122 120 120 120 120 118 118 118 120 120
27 RC 120 120 120 120 118 118 116 116 116 118 118 118
28 RC 140 140 140 140 140 140 140 138 138 138 140 140
29 RC 140 140 138 138 138 138 138 140 140 140 140 140
30 RC 120 110 120 120 120 120 120 120 120 120 120 120
GROUP ROPIVACAINE CLONIDINE SYSTOLIC BLOOD PRESSURE(mmhg)
S.No GROUP 0 MIN 5MIN 10 MIN 20 MIN  30MIN 40 MIN 50 MIN 60 MIN 120 MIN 180 MIN 240 MIN  300 MIN
1 RC 80 80 80 78 78 78 78 78 80 80 80 80
2 RC 80 84 84 80 80 76 76 76 76 76 76 76
3 RC 70 70 70 70 66 66 66 66 68 68 68 68
4 RC 78 80 78 78 78 78 76 70 70 70 70 70
5 RC 80 82 82 80 80 80 80 80 80 80 80 80
6 RC 80 80 80 80 78 78 78 78 78 78 78 78
7 RC 70 70 72 72 70 70 70 70 70 70 70 70
8 RC 70 70 68 68 68 68 68 70 70 68 70 70
9 RC 80 80 78 78 78 80 80 80 80 80 80 80
10 RC 80 80 80 80 78 78 76 74 74 74 72 74
11 RC 70 70 74 74 70 70 70 70 70 70 70 70
12 RC 80 80 80 80 80 78 80 80 80 78 78 78
13 RC 80 80 80 80 78 76 78 80 80 78 78 78
14 RC 70 70 70 70 68 68 68 68 66 64 66 66
15 RC 70 70 70 70 70 68 68 68 68 66 66 66
16 RC 70 70 70 70 70 70 70 68 70 70 70 70
17 RC 80 82 82 80 80 80 80 80 80 80 80 80
18 RC 80 80 80 80 78 78 80 80 80 78 80 80
19 RC 80 80 80 80 78 76 76 76 76 74 74 74
20 RC 70 70 70 68 70 70 70 70 68 68 66 66
21 RC 80 80 80 80 78 80 80 78 78 76 76 76
22 RC 80 82 82 80 80 78 78 78 76 76 76 76
23 RC 70 70 70 70 68 68 68 68 68 66 66 66
24 RC 70 70 70 70 70 68 70 70 70 70 70 70
25 RC 80 80 80 80 80 80 80 80 80 80 78 78
26 RC 70 70 72 70 70 68 68 68 66 66 66 64
27 RC 70 70 70 70 70 70 70 68 68 68 68 68
28 RC 70 72 70 70 70 70 72 70 68 68 68 68
29 RC 80 80 80 80 78 78 78 78 78 78 78 76
30 RC 80 80 80 78 78 78 78 76 76 76 76 76
GROUP ROPIVACAINE CLONIDINE DIASTOLIC BLOOD PRESSURE(mmhg)
CLONIDINE AS AN ADJUVANT TO ROPIVACAINE IN 
SCIATIC FEMORAL BLOCK FOR LOWER LIMB SURGERY 
ABSTRACT 
Background 
      This is a prospective randomized double blinded study of evaluation of 
clonidine as an adjuvant to ropivacaine  in sciatic femoral block  for  lower 
limb surgery . 
Methods 
      60 Patients of ASA grade I or II undergoing upper limb surgeries were 
randomly assigned into two groups, groups R and RC. Surgery was done 
under sciatic femoral nerve block through Labats approach after 
confirmation with nerve stimulator. The patients in group R received 30 ml 
at 0.75% Ropivacaine and 0.4 ml Normal saline. In group RC received 
30ml at 0.75% Ropivacaine and 60 micrograms clonidine. In this 30ml 
mixture, 18 ml given in sciatic nerve block and 12 ml given in femoral 
nerve block. Parameters observed were time of onset of sensory and motor 
block, duration of sensory and motor blockade, duration of post operative 
analgesia, sedation score and side effects. 
 
Observations 
      There is no significant difference in the onset of sensory and motor 
blockade in ropivacaine-clonidine group when compared to ropivacaine 
group. The addition of clonidine to ropivacaine increases the duration of 
sensory blockade  by 184 minutes, duration of motor blockade by 157 
minutes and  the duration of post operative analgesia by 192 minutes when 
compared to ropivacaine alone (P<0.05). In this study, no significant 
difference was observed with respect to the pulse rate, systolic and diastolic 
blood pressure, sedation and saturation. 
Conclusion 
      The addition of clonidine to ropivacaine in sciatic femoral nerve block 
shows no difference in the onset of sensory and motor blockade but 
prolongs the duration of both sensory and motor blockade and post 
operative analgesia, when compared to ropivacaine alone. 
Key words 
Sciatic femoral nerve block, clonidine,  ropivacaine, nerve stimulator. 
 
 
 
